endometriosis
Women's health · 2024–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| dienogest Treatment of endometriosis in patients requiring hormonal therapy, particularly those unable to use estrogen-based treatment. | Jul 2024 | Recommended with restriction | input received National Aboriginal Community Controlled Health Organisation |
| relugolix with estradiol and norethisterone acetate Treatment of moderate to severe pain associated with endometriosis in women who have failed to gain adequate pain relief from existing treatments. | Mar 2024 | Recommended with restriction | 3 individuals Pelvic Pain Foundation |
| relugolix with estradiol and norethisterone acetate Treatment of moderate to severe pain associated with endometriosis in women who have failed to gain adequate pain relief from hormonal treatments and… | Nov 2024 | Noted | 9 individuals Research Institute |
Who spoke
National Aboriginal Community Controlled Health Organisation · Pelvic Pain Foundation · Research Institute
What the PBS pays
$28M in government benefit over 2024–25, across 1,283,370 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| relugolix with estradiol and norethisterone acetate | $27M |
| dienogest | $0.8M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| nafarelinSYNAREL NASAL SPRAY nafarelin (as acetate) 2mg/mL | 1994 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 3 of 3 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.